Latest Breaking News On - Patients with recurrent nmibc or mibc harboring select fgfr mutations fusions - Page 1 : comparemela.com

Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.

Comunidad autonoma de catalunaUrology serviceAntoni vilasecaCancers symposiumUniversitat de barcelonaBacillus calmette guerinNew methods of delivery for erdafitinibIntravesical drug delivery systemTar 210Patients with non muscle invasive bladder cancerOral delivery of erdafitinibThor 2 trialPatients with recurrent nmibc or mibc harboring select fgfr mutations fusionsHospital clínic de barcelona